Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
Phase 1
Completed
- Conditions
- Obesity
- Registration Number
- NCT00331175
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
- BMI 27-35 kg/m2
Exclusion Criteria
- Women of childbearing potential
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Food intake
- Secondary Outcome Measures
Name Time Method Plasma biomarkers, safety, toleration
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which Peptide YY3-36 suppresses appetite in overweight adults?
How does intravenous Peptide YY3-36 compare to GLP-1 receptor agonists in weight management efficacy?
Which biomarkers correlate with improved food intake reduction following Peptide YY3-36 administration?
What adverse events are associated with intravenous Peptide YY3-36 in phase 1 trials for obesity?
Are there synergistic effects when combining Peptide YY3-36 with other anti-obesity drugs like liraglutide or orlistat?
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸New Haven, Connecticut, United States
Pfizer Investigational Site🇺🇸New Haven, Connecticut, United States